Mark Litton
Chief Executive Officer at ATHIRA PHARMA, INC.
Net worth: 315 045 $ as of 2024-04-29
Mark Litton active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ATHIRA PHARMA, INC. | Director/Board Member | - | - |
| Chief Executive Officer | 2021-06-15 | - | |
| President | 2021-06-15 | - | |
| Chief Operating Officer | 2019-07-10 | 2021-10-17 | |
Lumen Bioscience, Inc.
 Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Director/Board Member | - | - |
Career history of Mark Litton
Former positions of Mark Litton
| Companies | Position | Start | End |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Chief Operating Officer | 2018-08-05 | 2019-04-15 |
| President | 2018-08-05 | 2019-04-15 | |
| ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 2003-12-31 | 2010-02-25 |
| Founder | 2003-12-31 | 2018-07-31 | |
| Public Communications Contact | 2003-12-31 | - | |
| Corporate Officer/Principal | 2003-12-31 | 2010-02-25 | |
| Corporate Secretary | 2003-12-31 | 2018-07-31 | |
| Treasurer | 2010-02-25 | 2018-07-31 | |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | 1998-12-31 | 2003-12-31 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 1996-12-31 | 1998-12-31 |
| DNAX Research, Inc. | Corporate Officer/Principal | 1990-12-31 | 1993-12-31 |
| Chiroscience Group Plc | Corporate Officer/Principal | 1998-12-31 | - |
Training of Mark Litton
| University of Stockholm | Doctorate Degree |
| Santa Clara University | Masters Business Admin |
| University of California, Santa Cruz | Undergraduate Degree |
Statistics
International
| United States | 9 |
| United Kingdom | 3 |
| Sweden | 2 |
Operational
| Corporate Officer/Principal | 5 |
| Director/Board Member | 3 |
| Chief Operating Officer | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
| Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
| DNAX Research, Inc. | |
| Chiroscience Group Plc | Commercial Services |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Mark Litton
- Experience